marginal significancep = 0.047
One randomized controlled trial supported this concept by comparing lamivudine administration to placebo in patients with cirrhosis and CHB, where HCC incidence assessed as a part of the composite outcome, was less frequent in the lamivudine group with a marginal significance ( p = 0.047) ( 9 ).